Key result
Intravenous immunoglobulin significantly decreased new coronary artery abnormalities at 30 days compared to placebo in children with Kawasaki disease.
Why the study?
Does intravenous immunoglobulin reduce new coronary artery abnormalities in children with Kawasaki disease?
Population
Children with Kawasaki disease (16 randomized controlled trials)
Comparison
Intravenous immunoglobulin, including various… vs Placebo or alternative doses/preparations of IVIG
Design
Meta-analysis
Follow-up
up to 60 days
Authors
Loading...
Supports early IVIG use to prevent coronary artery abnormalities in Kawasaki disease; confirms efficacy from aggregated RCTs and bolsters guideline-directed care.
Meta-Analysis
Yes
Does intravenous immunoglobulin reduce new coronary artery abnormalities in children with Kawasaki disease?
Relative Risk: 0.74 (95% CI 0.61–0.9)
IVIG, particularly as a 2 gm/kg single dose, significantly reduces the risk of new coronary artery abnormalities in children with Kawasaki disease when administered within 10 days of symptom onset.
Oates-Whitehead et al. (2003) conducted a meta-analysis in Kawasaki disease. Intravenous immunoglobulin (IVIG) vs. Placebo or no treatment (aspirin) was evaluated on New coronary artery abnormalities (CAAs) at 30 days (RR 0.74, 95% CI 0.61 to 0.90). Intravenous immunoglobulin significantly decreased new coronary artery abnormalities at 30 days compared to placebo in children with Kawasaki disease.
Synapse has enriched one closely related paper. Consider it for comparative context: